Canada markets open in 2 hours 41 minutes
  • S&P/TSX

    21,216.15
    +3.75 (+0.02%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.92 (+0.21%)
     
  • CAD/USD

    0.8093
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    84.45
    +0.69 (+0.82%)
     
  • BTC-CAD

    77,322.43
    +1,630.79 (+2.15%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • GOLD FUTURES

    1,800.20
    +3.90 (+0.22%)
     
  • RUSSELL 2000

    2,291.27
    -4.91 (-0.21%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,380.50
    +39.50 (+0.26%)
     
  • VOLATILITY

    15.89
    +0.88 (+5.86%)
     
  • FTSE

    7,241.55
    +37.00 (+0.51%)
     
  • NIKKEI 225

    28,600.41
    -204.44 (-0.71%)
     
  • CAD/EUR

    0.6960
    +0.0018 (+0.26%)
     

2021 Report on Corneal Neovascularization Drugs In Development - ResearchAndMarkets.com

·4 min read

DUBLIN, September 22, 2021--(BUSINESS WIRE)--The "Corneal Neovascularization (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape. Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors include infections, trauma to the eye, chemical burns, immune system diseases and certain other eye conditions, such as uveitis and glaucoma. Symptoms include irritation in the eyes, dryness and pink eye or conjunctivitis and light sensitivity.

This report provides comprehensive information on the therapeutics under development for Corneal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Corneal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology).

  • The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Corneal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Chengdu Kanghong Pharmaceuticals Group Co Ltd

  • EyeGate Pharmaceuticals Inc

  • FortuneRock (China) Ltd

  • Gene Signal International SA

  • Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd

  • Singh Biotechnology LLC

  • Wntgen LLC

For more information about this report visit https://www.researchandmarkets.com/r/35iokp

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005440/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting